Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New data suggests chemotherapy patients benefit from heart failure treatment

25.09.2002


More than one-third of patients undergoing chemotherapy at risk for heart failure



Researchers at The University of Texas M. D. Anderson Cancer Center have found that cancer patients who develop heart failure as a result of chemotherapy treatment can be effectively treated, with the condition potentially reversed, when standard medicated therapy for heart failure is utilized.

The findings were presented today at the Sixth Annual Scientific Meeting of the Heart Failure Society of America in Boca Raton by Dr. Jean-Bernard Durand, assistant professor in the Department of Cardiology and director of Cardiomyopathy Service at M. D. Anderson.


The retrospective studies showed that patients treated with ACE-inhibitors and the beta-blocking agent, carvedilol, had significant improvements in two measures of heart failure: ejection fraction and New York Heart Association (NYHA) functional class . Previously, many cancer patients endured the invasive insertion of cardiac devices or full heart transplants in an effort to treat heart failure resulting from chemotherapy treatment.

The research has not been traditionally studied in cancer patients, and is believed to be the first to evaluate the treatment of heart failure using standard medication therapy in patients undergoing chemotherapy.

"Until now, heart failure was thought to be irreversible in chemotherapy patients with many cardiologists advising patients who develop the condition to reduce their chemotherapy regimens," say Dr. Durand, lead investigator for the study. "This data suggests that patients can continue their chemotherapy regimens, yet effectively reduce their risk of worsening heart failure and the eventual need for heart transplantation."

Heart failure develops when the heart is weakened and unable to pump blood efficiently through the body. It commonly results from damage to the heart after a heart attack, high blood pressure or diabetes. According to Dr. Durand, however, chemotherapeutic agents -- particularly at high doses -- may also cause direct injury to the heart, which can be potentially fatal or result in the need for heart transplantation and/or mechanical assistance heart devices. Dr. Durand says that 30 percent to 50 percent of chemotherapy patients will develop heart failure.

Dr. Durand presented today two retrospective studies evaluating the treatment of heart failure in chemotherapy patients. In one retrospective study, investigators reviewed the medical records of fifteen cancer inpatients with class IV heart failure evaluated in M. D. Anderson’s cardiomyopathy clinic. Cancer diagnosis, ejection fraction, recorded symptoms and hemodynamic data were examined before and after the use of intravenous inotropic agents, beta-blocking agents, ACE inhibitors and diuretics. Fourteen of the 15 patients achieved significant recovery of cardiac function and improvement in NYHA functional class following treatment and 13 patients were successfully discharged on a regimen of ACE inhibitors in combination with carvedilol.

In a second retrospective study, Dr. Durand and investigators reviewed the medical records from 16 cancer outpatients with mild to severe heart failure, diagnosed at initial evaluation in M. D. Anderson’s cardiomyopathy clinic. All 16 patients received standard combination therapy for heart failure, which included ACE inhibitors, diuretics and the beta-blocking agent carvedilol, unless unable to tolerate therapy. Ten patients had baseline left ventricular ejection fraction (LVEF) of less than 40 percent and six patients had LVEF of greater than 40 percent.

Results showed that carvedilol treatment alone yielded a mean increase in ejection fraction units in both groups of patients, 22 percent and 15 percent, respectively. Carvedilol in combination with an ACE inhibitor yielded a 25 percent increase in ejection fraction in patients with LVEF less than 40 percent and a 16 percent increase in patients with LVEF more than 40 percent.

"The data demonstrate that chemotherapy-induced heart failure may be reversible with standard medicated therapy for the condition," says Dr. Durand. "The implications of this research could lead to better chemotherapy regimens for patients without concern for developing a potentially fatal condition as a result of their cancer treatment."

M. D. Anderson researchers have proposed conducting a broader-scaled study in the near future to further analyze these observations.

Laura Sussman | EurekAlert!

More articles from Health and Medicine:

nachricht Purdue cancer identity technology makes it easier to find a tumor's 'address'
16.11.2018 | Purdue University

nachricht Microgel powder fights infection and helps wounds heal
14.11.2018 | Michigan Technological University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: UNH scientists help provide first-ever views of elusive energy explosion

Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.

Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...

Im Focus: A Chip with Blood Vessels

Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.

Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...

Im Focus: A Leap Into Quantum Technology

Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.

In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...

Im Focus: Research icebreaker Polarstern begins the Antarctic season

What does it look like below the ice shelf of the calved massive iceberg A68?

On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.

Im Focus: Penn engineers develop ultrathin, ultralight 'nanocardboard'

When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure

Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

“3rd Conference on Laser Polishing – LaP 2018” Attracts International Experts and Users

09.11.2018 | Event News

On the brain’s ability to find the right direction

06.11.2018 | Event News

European Space Talks: Weltraumschrott – eine Gefahr für die Gesellschaft?

23.10.2018 | Event News

 
Latest News

Purdue cancer identity technology makes it easier to find a tumor's 'address'

16.11.2018 | Health and Medicine

Good preparation is half the digestion

16.11.2018 | Life Sciences

Microscope measures muscle weakness

16.11.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>